 |
|
|
| |
Selection of Cabotegravir Dosing Regimens For HIV Treatment and
Pre-Exposure Prophylaxis (PrEP) in Adolescents by Leveraging
Adult Data
|
| |
| |
AIDS 2022 July 29-Aug 2 Montreal
Kelong Han1, Navin Goyal1, Susan L. Ford2, S. Y. Amy Cheung1, Lionel Tan3, Cindy McCoig4, Parul Patel2, Edmund Capparelli5, Brookie Best5, Mark Marzinke6,
Carolyn Bolton Moore7,8, Aditya H. Gaur9, Conn Harrington2, David Izard1, Jenny Huang1, Mark Baker10
1GlaxoSmithKline, Collegeville, PA, United States; 2GlaxoSmithKline, Research Triangle Park, NC, United States; 3ViiV Healthcare, Brentford, United Kingdom; 4ViiV Healthcare, Tres Cantos, Madrid, Spain; 5University of California San Diego, La Jolla, CA, United States; 6Johns Hopkins University, Baltimore, MD, United States; 7Center for Infectious Disease Research in Zambia, Lusaka, Zambia; 8University of Alabama at Birmingham, Birmingham, AL, United States; 9St. Jude Children’s Research Hospital, Memphis, TN, United States; 10ViiV Healthcare, Nyon, Switzerland
|
| |
|
|
|
|
|
